500
Participants
Start Date
December 24, 2020
Primary Completion Date
January 24, 2029
Study Completion Date
April 24, 2029
PASCA intervention
"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
Centre Leon Berard, Lyon
Malakoff-Humanis
UNKNOWN
Fondation Apicil
OTHER
Fédération Leucémie Espoir
UNKNOWN
Biogaran
UNKNOWN
Le défi Anthony
UNKNOWN
Novartis
INDUSTRY
Roche Pharma AG
INDUSTRY
Centre Leon Berard
OTHER